Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is MacroGenics (MGNX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

MacroGenics is a member of our Medical group, which includes 913 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. MacroGenics is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for MGNX's full-year earnings has moved 35.9% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the most recent data, MGNX has returned 159% so far this year. In comparison, Medical companies have returned an average of 7.1%. This shows that MacroGenics is outperforming its peers so far this year.

CareDx (CDNA) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 146.9%.

Over the past three months, CareDx's consensus EPS estimate for the current year has increased 113.6%. The stock currently has a Zacks Rank #1 (Strong Buy).

Looking more specifically, MacroGenics belongs to the Medical - Products industry, a group that includes 84 individual stocks and currently sits at #97 in the Zacks Industry Rank. On average, stocks in this group have lost 13.7% this year, meaning that MGNX is performing better in terms of year-to-date returns.

On the other hand, CareDx belongs to the Medical Services industry. This 72-stock industry is currently ranked #100. The industry has moved +1.7% year to date.

Going forward, investors interested in Medical stocks should continue to pay close attention to MacroGenics and CareDx as they could maintain their solid performance.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

MacroGenics, Inc. (MGNX): Free Stock Analysis Report

 

CareDx, Inc. (CDNA): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research